These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706 [TBL] [Abstract][Full Text] [Related]
67. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages. Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Casey M; Segawa K; Law SC; Sabdia MB; Nowlan B; Salik B; Lee C; Winterford C; Pearson S; Madore J; Dougall WC; Gandhi MK; Nakamura K Leukemia; 2023 Feb; 37(2):379-387. PubMed ID: 36539557 [TBL] [Abstract][Full Text] [Related]
69. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity. Wang X; Wang Y; Hu J; Xu H Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544 [TBL] [Abstract][Full Text] [Related]
70. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
71. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248 [TBL] [Abstract][Full Text] [Related]
72. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Tong B; Wang M Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847 [TBL] [Abstract][Full Text] [Related]
73. Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential. Ma L; Zhu M; Gai J; Li G; Chang Q; Qiao P; Cao L; Chen W; Zhang S; Wan Y J Nanobiotechnology; 2020 Jan; 18(1):12. PubMed ID: 31931812 [TBL] [Abstract][Full Text] [Related]
74. Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal. Li C; Liu Y; Li D; Wang Q; Zhou S; Zhang H; Wang Y; He Z; Liu H; Sun J Theranostics; 2022; 12(10):4581-4598. PubMed ID: 35832081 [No Abstract] [Full Text] [Related]
75. Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma. Gifford G; Stevenson W; Best G Leuk Lymphoma; 2020 Dec; 61(13):3165-3176. PubMed ID: 32723130 [TBL] [Abstract][Full Text] [Related]
77. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592 [TBL] [Abstract][Full Text] [Related]
78. A novel CD47-blocking peptide fused to pro-apoptotic KLA repeat inhibits lung cancer growth in mice. Pan L; Hu L; Chen M; Song Y; Chen Z; Gu Y; Li C; Jiang Z Cancer Immunol Immunother; 2023 Dec; 72(12):4179-4194. PubMed ID: 37831145 [TBL] [Abstract][Full Text] [Related]
79. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061 [No Abstract] [Full Text] [Related]